BackTable Urology
Ep. 188 Testosterone Therapy Today: Clinical Advances and Safety with Dr. Abraham Morgentaler
Dr. Abraham Morgentaler
And he went on to work also with ovarian cancer, breast cancer, uterine cancer. But he created the difficulty because he saw this as kind of like an either-or situation. If you remove testosterone, prostate cancers would shrink. And the biomarker they used then, which was called acid phosphatase before PSA, would go down just like we would expect PSA to go down.
0
💬
0
Comments
Log in to comment.
There are no comments yet.